Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
Neurology
.
2020 Mar 31;94(13):594.
doi: 10.1212/WNL.0000000000009185.
Authors
John Breitner
1
,
Pierre-Francois Meyer
1
Affiliation
1
(Montreal).
PMID:
32229636
DOI:
10.1212/WNL.0000000000009185
No abstract available
Publication types
Comment
MeSH terms
Alzheimer Disease*
Anti-Inflammatory Agents, Non-Steroidal
Asymptomatic Diseases
Humans
Naproxen*
Substances
Anti-Inflammatory Agents, Non-Steroidal
Naproxen